The International LAM Registry: a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platform.

BACKGROUND: A relative inability to capture a sufficiently large patient population in any one geographic location has traditionally limited research into rare diseases. METHODS AND RESULTS: Clinicians interested in the rare disease lymphangioleiomyomatosis (LAM) have worked with the LAM Treatment Alliance, the MIT Media Lab, and Clozure Associates to cooperate in the design of a state-of-the-art data coordination platform that can be used for clinical trials and other research focused on the global LAM patient population. This platform is a component of a set of web-based resources, including a patient self-report data portal, aimed at accelerating research in rare diseases in a rigorous fashion. CONCLUSIONS: Collaboration between clinicians, researchers, advocacy groups, and patients can create essential community resource infrastructure to accelerate rare disease research. The International LAM Registry is an example of such an effort. 82.

Ein Instrument der parlamentarischen Mitwirkung im Bereich der schweizerischen Aussenpolitik : die Information und Konsultation gemäss Art. 152 Parlamentsgesetz

Dass der Weg der parlamentarischen Mitwirkung im Bereich der Aussenpolitik steinig werden sollte, widerspiegelte sich bereits in der Entstehungsgeschichte der Aussenpolitischen Kommissionen (APK). Diese haben zum heutigen Zeitpunkt unter anderem dafür zu sorgen, dass das Parlament seine Mitwirkungsrechte in auswärtigen Angelegenheiten frühzeitig und wirk¬sam wahrnehmen kann. Nebst verschiedensten Instrumenten auf Verfassungs- und Gesetzesebene steht den APK ein wichtiges Mitwirkungsinstrument zur Verfügung: die Information und Konsultation gemäss Art. 152 Parlamentsgesetz (ParlG). Seit Inkrafttreten dieser Bestimmung im Dezember 2003 offenbart sich jedoch, dass sich die praktische Umsetzung des Gesetzesartikels mit den damaligen Vorstellungen des Gesetzgebers anlässlich der Erarbeitung dieses parlamentarischen Instrumentes nicht deckt. Der Gesetzgeber wies seiner¬zeit auf das für die Umsetzung bedeutende Vertrauensverhältnis zwischen Bundesrat und Parlament hin. Allerdings beeinflussen nun Spannungen und Konkurrenz zwischen der Exekutive und der Legislative die Umsetzung von Art. 152 ParlG. Die vorliegende Arbeit versucht, die geschichtlichen Hintergründe, die Entstehung, den Sinn und Zweck sowie die Praxis von Art. 152 ParlG vor dem Hintergrund des erwähnten Spannungsfelds und im Zusammenspiel mit den weiteren Mitwirkungsinstrumenten im Bereich der Aussenpolitik darzulegen. Comme le montre déjà l'historique des Commissions de politique extérieure (CPE), la participation du Parlement à la politique extérieure n'est pas dénuée d'obstacles. A l'heure actuelle, les CPE doivent notamment faire en sorte que le Parlement puisse faire valoir, en amont et avec efficacité, son droit de participation dans le domaine de la politique étrangère de la Suisse. Outre divers instruments figurant dans la Constitution et les lois, les CPE disposent d'un important moyen de participation: l'information et la consultation au sens de l'art. 152 de la loi sur le Parlement (LParl). Depuis l'entrée en vigueur de cette disposition en décembre 2003, il s'avère toutefois que l'application concrète de cet article de loi ne ré¬pond pas entièrement aux attentes du législateur lors de l'élaboration de cet instrument parlementaire. En effet, le législateur s'était alors basé sur la relation de confiance entre le Conseil fédéral et le Parlement, relation essentielle à la mise en oeuvre de cet article. La pratique montre cependant que la mise en oeuvre de l'art. 152 LParl est influencée par des tensions et par une relation de concurrence existant entre l'exécutif et le législatif. Le présent travail entend exposer le contexte historique de l'art. 152 LParl, son élaboration, son but et sa mise en oeuvre, tout en tenant compte des éléments de tension et des autres instruments permettant la participation en matière de politique extérieure.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

BACKGROUND: Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up. METHODS: BIG 1-98 is a randomised, phase 3, double-blind trial of postmenopausal women with hormone receptor-positive early breast cancer that compares 5 years of tamoxifen or letrozole monotherapy, or sequential treatment with 2 years of one of these drugs followed by 3 years of the other. Randomisation was done with permuted blocks, and stratified according to the two-arm or four-arm randomisation option, participating institution, and chemotherapy use. Patients, investigators, data managers, and medical reviewers were masked. The primary efficacy endpoint was disease-free survival (events were invasive breast cancer relapse, second primaries [contralateral breast and non-breast], or death without previous cancer event). Secondary endpoints were overall survival, distant recurrence-free interval (DRFI), and breast cancer-free interval (BCFI). The monotherapy comparison included patients randomly assigned to tamoxifen or letrozole for 5 years. In 2005, after a significant disease-free survival benefit was reported for letrozole as compared with tamoxifen, a protocol amendment facilitated the crossover to letrozole of patients who were still receiving tamoxifen alone; Cox models and Kaplan-Meier estimates with inverse probability of censoring weighting (IPCW) are used to account for selective crossover to letrozole of patients (n=619) in the tamoxifen arm. Comparison of sequential treatments to letrozole monotherapy included patients enrolled and randomly assigned to letrozole for 5 years, letrozole for 2 years followed by tamoxifen for 3 years, or tamoxifen for 2 years followed by letrozole for 3 years. Treatment has ended for all patients and detailed safety results for adverse events that occurred during the 5 years of treatment have been reported elsewhere. Follow-up is continuing for those enrolled in the four-arm option. BIG 1-98 is registered at clinicaltrials.govNCT00004205. FINDINGS: 8010 patients were included in the trial, with a median follow-up of 8·1 years (range 0-12·4). 2459 were randomly assigned to monotherapy with tamoxifen for 5 years and 2463 to monotherapy with letrozole for 5 years. In the four-arm option of the trial, 1546 were randomly assigned to letrozole for 5 years, 1548 to tamoxifen for 5 years, 1540 to letrozole for 2 years followed by tamoxifen for 3 years, and 1548 to tamoxifen for 2 years followed by letrozole for 3 years. At a median follow-up of 8·7 years from randomisation (range 0-12·4), letrozole monotherapy was significantly better than tamoxifen, whether by IPCW or intention-to-treat analysis (IPCW disease-free survival HR 0·82 [95% CI 0·74-0·92], overall survival HR 0·79 [0·69-0·90], DRFI HR 0·79 [0·68-0·92], BCFI HR 0·80 [0·70-0·92]; intention-to-treat disease-free survival HR 0·86 [0·78-0·96], overall survival HR 0·87 [0·77-0·999], DRFI HR 0·86 [0·74-0·998], BCFI HR 0·86 [0·76-0·98]). At a median follow-up of 8·0 years from randomisation (range 0-11·2) for the comparison of the sequential groups with letrozole monotherapy, there were no statistically significant differences in any of the four endpoints for either sequence. 8-year intention-to-treat estimates (each with SE ≤1·1%) for letrozole monotherapy, letrozole followed by tamoxifen, and tamoxifen followed by letrozole were 78·6%, 77·8%, 77·3% for disease-free survival; 87·5%, 87·7%, 85·9% for overall survival; 89·9%, 88·7%, 88·1% for DRFI; and 86·1%, 85·3%, 84·3% for BCFI. INTERPRETATION: For postmenopausal women with endocrine-responsive early breast cancer, a reduction in breast cancer recurrence and mortality is obtained by letrozole monotherapy when compared with tamoxifen montherapy. Sequential treatments involving tamoxifen and letrozole do not improve outcome compared with letrozole monotherapy, but might be useful strategies when considering an individual patient's risk of recurrence and treatment tolerability. FUNDING: Novartis, United States National Cancer Institute, International Breast Cancer Study Group.

State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology.

Integrated approaches using different in vitro methods in combination with bioinformatics can (i) increase the success rate and speed of drug development; (ii) improve the accuracy of toxicological risk assessment; and (iii) increase our understanding of disease. Three-dimensional (3D) cell culture models are important building blocks of this strategy which has emerged during the last years. The majority of these models are organotypic, i.e., they aim to reproduce major functions of an organ or organ system. This implies in many cases that more than one cell type forms the 3D structure, and often matrix elements play an important role. This review summarizes the state of the art concerning commonalities of the different models. For instance, the theory of mass transport/metabolite exchange in 3D systems and the special analytical requirements for test endpoints in organotypic cultures are discussed in detail. In the next part, 3D model systems for selected organs--liver, lung, skin, brain--are presented and characterized in dedicated chapters. Also, 3D approaches to the modeling of tumors are presented and discussed. All chapters give a historical background, illustrate the large variety of approaches, and highlight up- and downsides as well as specific requirements. Moreover, they refer to the application in disease modeling, drug discovery and safety assessment. Finally, consensus recommendations indicate a roadmap for the successful implementation of 3D models in routine screening. It is expected that the use of such models will accelerate progress by reducing error rates and wrong predictions from compound testing.